SyneuRx International (Taiwan) Corp. Discovers Potential Drug DGDX for Treating Mental Disorders and Neurodegenerative Disorders

Press Release

April 12, 2024

New Taipei City, Taiwan – April 12, 2024 – SyneuRx (TPEX:6575) research team has recently published a groundbreaking study in the international journal Biomedicines, unveiling a potential new drug, DGDX, for the treatment of mental disorders and neurodegenerative disorders. This study, conducted in collaboration with researchers from SyneuRx International (Taiwan) Corp. and the University of California, Los Angeles (UCLA), aims to regulate the function of N-methyl-D-aspartate (NMDA) receptors in the brain to improve symptoms associated with these conditions. 

NMDA receptors play a crucial role in learning, memory, and neural plasticity. Their dysfunction is closely linked to disorders such as schizophrenia, depression, and Alzheimer’s disease. While previous treatments have primarily focused on adjusting NMDA receptor activity, this study found that DGDX has dual regulatory mechanism. DGDX dynamically influences the production of D-serine, an important NMDA receptor co-agonist, thereby adjusting NMDA receptor activity and the brain function.

Animal studies have shown that DGDX effectively mitigates behavioral abnormalities caused by NMDA dysfunction, including reducing hyperactivity, enhancing sensory-motor gating, and improving memory and learning performance. These findings suggest that DGDX could become a promising treatment option for schizophrenia, Alzheimer’s disease, depression, and other related disorders.

The research team plans to further evaluate the long-term safety and clinical potential of DGDX, with future clinical trials aiming at confirming its effectiveness and scope of application. This breakthrough discovery offers new possibilities for the treatment of neurological and psychiatric disorders.

Original Paper Information:

📄 The Development of a Regulator of Human Serine Racemase for N-Methyl-D-aspartate Function

📌 Published in Biomedicines (April 12, 2024)

🔗 Full paper: https://doi.org/10.3390/biomedicines12040853